XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $261K invested in XTL Biopharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
2.08% more ownership
Funds ownership: 0% → 2.08% (+2.1%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
13% less capital invested
Capital invested by funds: $299K → $261K (-$37.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$7.65K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31.3K |
| 2 |
Morgan Stanley
New York
|
-$2.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $227K | – | – | – |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $20K | +$7.65K | +1,576 | +58% |
|
|
3
Morgan Stanley
New York
| $12.6K | -$2.72K | -560 | -17% |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.52K | +$1.62K | +334 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$31.3K | -6,303 | Closed |
|
XTLB Hedge Fund Activity: Q2 2025 in Review
4 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2025, worth a combined $261K — down 13% from $299K a quarter earlier.
Fund positioning in XTLB was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was RhumbLine Advisers, adding an estimated $7.65K. The largest seller was Citadel Advisors, exiting entirely with an estimated $31.3K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $261K of XTL Biopharmaceuticals stock for Q2 2025, down 13% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q2 2025 was RhumbLine Advisers, an estimated $7.65K added.
- The largest XTL Biopharmaceuticals seller in Q2 2025 was Citadel Advisors, an estimated $31.3K sold.
Based on aggregated 13F filings for Q2 2025.